BRISTOL-MYERS SQUIBB COMPANY Net Income
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Net Income of $3.32 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-07-30
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) attributable to parent for the quarter ending 2026-06-30 was $3.32B, a 153.21% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) attributable to parent for the quarter ending 2026-03-31 was $2.68B, a 9.00% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) attributable to parent for the quarter ending 2025-12-31 was $1.09B, a 1409.72% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) attributable to parent for the quarter ending 2025-09-30 was $2.20B, a 81.75% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) attributable to parent for fiscal 2025 was $7.05B.
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) attributable to parent for fiscal 2024 was -$8.95B, a 211.50% decline from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) attributable to parent for fiscal 2023 was $8.03B, a 26.84% increase from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY net income (loss) attributable to parent for fiscal 2022 was $6.33B, a 9.54% decline from fiscal 2021.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.32B 10-Q · filed 2026-07-30 | $5.99B 10-Q · filed 2026-07-30 | $7.08B derived: sum of 3 quarters · filed 2026-07-30 | $9.28B derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $2.68B 10-Q · filed 2026-04-30 | $3.76B derived: sum of 2 quarters · filed 2026-04-30 | $5.96B derived: sum of 3 quarters · filed 2026-04-30 | $7.28B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $1.09B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $3.29B derived: sum of 2 quarters · filed 2026-02-11 | $4.60B derived: sum of 3 quarters · filed 2026-07-30 | $7.05B 10-K · filed 2026-02-11 |
| 2025-09-30 | $2.20B 10-Q · filed 2025-10-30 | $3.51B derived: sum of 2 quarters · filed 2026-07-30 | $5.97B 10-Q · filed 2025-10-30 | $6.04B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $1.31B 10-Q · filed 2026-07-30 | $3.77B 10-Q · filed 2026-07-30 | $3.84B derived: sum of 3 quarters · filed 2026-07-30 | $5.05B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $2.46B 10-Q · filed 2026-04-30 | $2.53B derived: sum of 2 quarters · filed 2026-04-30 | $3.74B derived: sum of 3 quarters · filed 2026-04-30 | $5.42B derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $72.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $1.28B derived: sum of 2 quarters · filed 2026-02-11 | $2.96B derived: sum of 3 quarters · filed 2026-02-11 | -$8.95B 10-K · filed 2026-02-11 |
| 2024-09-30 | $1.21B 10-Q · filed 2025-10-30 | $2.89B derived: sum of 2 quarters · filed 2025-10-30 | -$9.02B 10-Q · filed 2025-10-30 | -$7.26B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | $1.68B 10-Q · filed 2025-07-31 | -$10.23B 10-Q · filed 2025-07-31 | -$8.47B derived: sum of 3 quarters · filed 2026-02-11 | -$6.54B derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | -$11.91B 10-Q · filed 2025-04-24 | -$10.15B derived: sum of 2 quarters · filed 2026-02-11 | -$8.22B derived: sum of 3 quarters · filed 2026-02-11 | -$6.15B derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $1.76B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $3.69B derived: sum of 2 quarters · filed 2026-02-11 | $5.76B derived: sum of 3 quarters · filed 2026-02-11 | $8.03B 10-K · filed 2026-02-11 |
| 2023-09-30 | $1.93B 10-Q · filed 2024-10-31 | $4.00B derived: sum of 2 quarters · filed 2024-10-31 | $6.26B 10-Q · filed 2024-10-31 | $8.29B derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $2.07B 10-Q · filed 2024-07-26 | $4.33B 10-Q · filed 2024-07-26 | $6.36B derived: sum of 3 quarters · filed 2025-02-12 | $7.96B derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | $2.26B 10-Q · filed 2024-04-25 | $4.28B derived: sum of 2 quarters · filed 2025-02-12 | $5.89B derived: sum of 3 quarters · filed 2025-02-12 | $7.31B derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | $2.02B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $3.63B derived: sum of 2 quarters · filed 2025-02-12 | $5.05B derived: sum of 3 quarters · filed 2025-02-12 | $6.33B 10-K · filed 2025-02-12 |
| 2022-09-30 | $1.61B 10-Q · filed 2023-10-26 | $3.03B derived: sum of 2 quarters · filed 2023-10-26 | $4.30B 10-Q · filed 2023-10-26 | $6.68B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $1.42B 10-Q · filed 2023-07-27 | $2.70B 10-Q · filed 2023-07-27 | $5.07B derived: sum of 3 quarters · filed 2024-02-13 | $6.62B derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $1.28B 10-Q · filed 2023-04-27 | $3.65B derived: sum of 2 quarters · filed 2024-02-13 | $5.20B derived: sum of 3 quarters · filed 2024-02-13 | $6.25B derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $2.37B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $3.92B derived: sum of 2 quarters · filed 2024-02-13 | $4.97B derived: sum of 3 quarters · filed 2024-02-13 | $6.99B 10-K · filed 2024-02-13 |
| 2021-09-30 | $1.55B 10-Q · filed 2022-10-26 | $2.60B derived: sum of 2 quarters · filed 2022-10-26 | $4.62B 10-Q · filed 2022-10-26 | -$5.41B derived: sum of 4 quarters · filed 2022-10-26 |
| 2021-06-30 | $1.05B 10-Q · filed 2022-07-27 | $3.08B 10-Q · filed 2022-07-27 | -$6.95B derived: sum of 3 quarters · filed 2022-07-27 | -$5.08B derived: sum of 4 quarters · filed 2022-07-27 |
| 2021-03-31 | $2.02B 10-Q · filed 2022-04-29 | -$8.01B derived: sum of 2 quarters · filed 2022-04-29 | -$6.13B derived: sum of 3 quarters · filed 2022-04-29 | -$6.22B derived: sum of 4 quarters · filed 2022-04-29 |
| 2020-12-31 | -$10.03B 10-K · filed 2021-02-10 | -$8.15B derived: sum of 2 quarters · filed 2021-10-27 | -$8.24B derived: sum of 3 quarters · filed 2021-10-27 | -$9.02B 10-K · filed 2023-02-14 |
| 2020-09-30 | $1.87B 10-Q · filed 2021-10-27 | $1.79B derived: sum of 2 quarters · filed 2021-10-27 | $1.01B 10-Q · filed 2021-10-27 | -$44.00M derived: sum of 4 quarters · filed 2021-10-27 |
| 2020-06-30 | -$85.00M 10-Q · filed 2021-07-28 | -$860.00M 10-Q · filed 2021-07-28 | -$1.92B derived: sum of 3 quarters · filed 2021-07-28 | -$563.00M derived: sum of 4 quarters · filed 2021-07-28 |
| 2020-03-31 | -$775.00M 10-Q · filed 2021-04-29 | -$1.83B derived: sum of 2 quarters · filed 2021-04-29 | -$478.00M derived: sum of 3 quarters · filed 2021-04-29 | $954.00M derived: sum of 4 quarters · filed 2021-04-29 |
| 2019-12-31 | -$1.06B 10-K · filed 2021-02-10 | $297.00M derived: sum of 2 quarters · filed 2021-02-10 | $1.73B derived: sum of 3 quarters · filed 2021-02-10 | $3.44B 10-K · filed 2022-02-09 |
| 2019-09-30 | $1.35B 10-K · filed 2021-02-10 | $2.79B derived: sum of 2 quarters · filed 2021-02-10 | $4.50B 10-Q · filed 2020-11-05 | $5.66B derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-06-30 | $1.43B 10-K · filed 2021-02-10 | $3.14B 10-Q · filed 2020-08-06 | $4.30B derived: sum of 3 quarters · filed 2021-02-10 | $6.20B derived: sum of 4 quarters · filed 2021-02-10 |
| 2019-03-31 | $1.71B 10-K · filed 2021-02-10 | $2.87B derived: sum of 2 quarters · filed 2021-02-10 | $4.77B derived: sum of 3 quarters · filed 2021-02-10 | $5.14B derived: sum of 4 quarters · filed 2021-02-10 |
| 2018-12-31 | $1.16B 10-K · filed 2020-02-24 | $3.06B derived: sum of 2 quarters · filed 2020-02-24 | $3.43B derived: sum of 3 quarters · filed 2020-02-24 | $4.92B 10-K · filed 2021-02-10 |
| 2018-09-30 | $1.90B 10-K · filed 2020-02-24 | $2.27B derived: sum of 2 quarters · filed 2020-02-24 | $3.76B 10-Q · filed 2019-10-31 | $1.43B derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-06-30 | $373.00M 10-K · filed 2020-02-24 | $1.86B 10-Q · filed 2019-07-25 | -$469.00M derived: sum of 3 quarters · filed 2020-02-24 | $376.00M derived: sum of 4 quarters · filed 2020-02-24 |
| 2018-03-31 | $1.49B 10-K · filed 2020-02-24 | -$842.00M derived: sum of 2 quarters · filed 2020-02-24 | $3.00M derived: sum of 3 quarters · filed 2020-02-24 | $919.00M derived: sum of 4 quarters · filed 2020-02-24 |
| 2017-12-31 | -$2.33B 10-K · filed 2019-02-25 | -$1.48B derived: sum of 2 quarters · filed 2019-02-25 | -$567.00M derived: sum of 3 quarters · filed 2019-02-25 | $1.01B 10-K · filed 2020-02-24 |
| 2017-09-30 | $845.00M 10-K · filed 2019-02-25 | $1.76B derived: sum of 2 quarters · filed 2019-02-25 | $3.33B 10-Q · filed 2018-10-25 | $4.23B derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-06-30 | $916.00M 10-K · filed 2019-02-25 | $2.49B 10-Q · filed 2018-07-26 | $3.38B derived: sum of 3 quarters · filed 2019-02-25 | $4.59B derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-03-31 | $1.57B 10-K · filed 2019-02-25 | $2.47B derived: sum of 2 quarters · filed 2019-02-25 | $3.67B derived: sum of 3 quarters · filed 2019-02-25 | $4.84B derived: sum of 4 quarters · filed 2019-02-25 |
| 2016-12-31 | $894.00M 10-K · filed 2018-02-13 | $2.10B derived: sum of 2 quarters · filed 2018-02-13 | $3.26B derived: sum of 3 quarters · filed 2018-02-13 | $4.46B 10-K · filed 2019-02-25 |
| 2016-09-30 | $1.20B 10-K · filed 2018-02-13 | $2.37B derived: sum of 2 quarters · filed 2018-02-13 | $3.56B 10-Q · filed 2017-10-26 | $3.37B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-06-30 | $1.17B 10-K · filed 2018-02-13 | $2.36B 10-Q · filed 2017-07-27 | $2.16B derived: sum of 3 quarters · filed 2018-02-13 | $2.87B derived: sum of 4 quarters · filed 2018-02-13 |
| 2016-03-31 | $1.20B 10-K · filed 2018-02-13 | $998.00M derived: sum of 2 quarters · filed 2018-02-13 | $1.70B derived: sum of 3 quarters · filed 2018-02-13 | $1.57B derived: sum of 4 quarters · filed 2018-02-13 |
| 2015-12-31 | -$197.00M 10-K · filed 2017-02-21 | $509.00M derived: sum of 2 quarters · filed 2017-02-21 | $379.00M derived: sum of 3 quarters · filed 2017-02-21 | $1.56B 10-K · filed 2018-02-13 |
| 2015-09-30 | $706.00M 10-K · filed 2017-02-21 | $576.00M derived: sum of 2 quarters · filed 2017-02-21 | $1.76B 10-Q · filed 2016-10-27 | $1.77B derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-06-30 | -$130.00M 10-K · filed 2017-02-21 | $1.06B 10-Q · filed 2016-07-28 | $1.07B derived: sum of 3 quarters · filed 2017-02-21 | $1.79B derived: sum of 4 quarters · filed 2017-02-21 |
| 2015-03-31 | $1.19B 10-K · filed 2017-02-21 | $1.20B derived: sum of 2 quarters · filed 2017-02-21 | $1.92B derived: sum of 3 quarters · filed 2017-02-21 | $2.25B derived: sum of 4 quarters · filed 2017-02-21 |
| 2014-12-31 | $13.00M 10-K · filed 2016-02-12 | $734.00M derived: sum of 2 quarters · filed 2016-02-12 | $1.07B derived: sum of 3 quarters · filed 2016-02-12 | $2.00B 10-K · filed 2017-02-21 |
| 2014-09-30 | $721.00M 10-K · filed 2016-02-12 | $1.05B derived: sum of 2 quarters · filed 2016-02-12 | $1.99B 10-Q · filed 2015-10-27 | $2.72B derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $333.00M 10-K · filed 2016-02-12 | $1.27B 10-Q · filed 2015-07-23 | $2.00B derived: sum of 3 quarters · filed 2016-02-12 | $2.69B derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $937.00M 10-K · filed 2016-02-12 | $1.66B derived: sum of 2 quarters · filed 2016-02-12 | $2.35B derived: sum of 3 quarters · filed 2016-02-12 | $2.89B derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $726.00M 10-K · filed 2015-02-13 | $1.42B derived: sum of 2 quarters · filed 2015-02-13 | $1.95B derived: sum of 3 quarters · filed 2015-02-13 | $2.56B 10-K · filed 2016-02-12 |
| 2013-09-30 | $692.00M 10-K · filed 2015-02-13 | $1.23B derived: sum of 2 quarters · filed 2015-02-13 | $1.84B 10-Q · filed 2014-10-24 | $2.76B derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $536.00M 10-K · filed 2015-02-13 | $1.15B 10-Q · filed 2014-07-24 | $2.07B derived: sum of 3 quarters · filed 2015-02-13 | $1.36B derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $609.00M 10-K · filed 2015-02-13 | $1.53B derived: sum of 2 quarters · filed 2015-02-13 | $823.00M derived: sum of 3 quarters · filed 2015-02-13 | $1.47B derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $925.00M 10-K · filed 2014-02-14 | $214.00M derived: sum of 2 quarters · filed 2014-02-14 | $859.00M derived: sum of 3 quarters · filed 2014-02-14 | $1.96B 10-K · filed 2015-02-13 |
| 2012-09-30 | -$711.00M 10-K · filed 2014-02-14 | -$66.00M derived: sum of 2 quarters · filed 2014-02-14 | $1.03B 10-Q · filed 2013-10-23 | $1.89B derived: sum of 4 quarters · filed 2014-02-14 |
| 2012-06-30 | $645.00M 10-K · filed 2014-02-14 | $1.75B 10-Q · filed 2013-07-25 | $2.60B derived: sum of 3 quarters · filed 2014-02-14 | $3.57B derived: sum of 4 quarters · filed 2014-02-14 |
| 2012-03-31 | $1.10B 10-K · filed 2014-02-14 | $1.95B derived: sum of 2 quarters · filed 2014-02-14 | $2.92B derived: sum of 3 quarters · filed 2014-02-14 | $3.82B derived: sum of 4 quarters · filed 2014-02-14 |
| 2011-12-31 | $852.00M 10-K · filed 2013-02-15 | $1.82B derived: sum of 2 quarters · filed 2013-02-15 | $2.72B derived: sum of 3 quarters · filed 2013-02-15 | $3.71B 10-K · filed 2014-02-14 |
| 2011-09-30 | $969.00M 10-K · filed 2013-02-15 | $1.87B derived: sum of 2 quarters · filed 2013-02-15 | $2.86B 10-Q · filed 2012-10-24 | $3.34B derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-06-30 | $902.00M 10-K · filed 2013-02-15 | $1.89B 10-Q · filed 2012-07-25 | $2.37B derived: sum of 3 quarters · filed 2013-02-15 | $3.32B derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-03-31 | $986.00M 10-K · filed 2013-02-15 | $1.47B derived: sum of 2 quarters · filed 2013-02-15 | $2.42B derived: sum of 3 quarters · filed 2013-02-15 | $3.35B derived: sum of 4 quarters · filed 2013-02-15 |
| 2010-12-31 | $483.00M 10-K · filed 2011-02-18 | $1.43B derived: sum of 2 quarters · filed 2011-10-27 | $2.36B derived: sum of 3 quarters · filed 2011-10-27 | $3.10B 10-K · filed 2013-02-15 |
| 2010-09-30 | $949.00M 10-Q · filed 2011-10-27 | $1.88B derived: sum of 2 quarters · filed 2011-10-27 | $2.62B 10-Q · filed 2011-10-27 | $10.64B derived: sum of 4 quarters · filed 2011-10-27 |
| 2010-06-30 | $927.00M 10-Q · filed 2011-07-28 | $1.67B 10-Q · filed 2011-07-28 | $9.70B derived: sum of 3 quarters · filed 2011-07-28 | $10.66B derived: sum of 4 quarters · filed 2011-07-28 |
| 2010-03-31 | $743.00M 10-Q · filed 2011-04-28 | $8.77B derived: sum of 2 quarters · filed 2011-04-28 | $9.73B derived: sum of 3 quarters · filed 2011-04-28 | $10.72B derived: sum of 4 quarters · filed 2011-04-28 |
| 2009-12-31 | $8.03B 10-K · filed 2011-02-18 | $8.99B derived: sum of 2 quarters · filed 2011-02-18 | $9.97B derived: sum of 3 quarters · filed 2011-02-18 | $10.61B 10-K · filed 2012-02-17 |
| 2009-09-30 | $966.00M 10-K · filed 2011-02-18 | $1.95B derived: sum of 2 quarters · filed 2011-02-18 | $2.59B 10-Q · filed 2010-10-26 | $3.83B derived: sum of 4 quarters · filed 2011-02-18 |
| 2009-06-30 | $983.00M 10-K · filed 2011-02-18 | $1.62B 10-Q · filed 2010-07-22 | $2.87B derived: sum of 3 quarters · filed 2011-02-18 | $5.44B derived: sum of 4 quarters · filed 2011-02-18 |
| 2009-03-31 | $638.00M 10-K · filed 2011-02-18 | $1.88B derived: sum of 2 quarters · filed 2011-02-18 | $4.46B derived: sum of 3 quarters · filed 2011-02-18 | $5.22B derived: sum of 4 quarters · filed 2011-02-18 |
| 2008-12-31 | $1.24B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18 | $3.82B derived: sum of 2 quarters · filed 2011-02-18 | $4.59B derived: sum of 3 quarters · filed 2011-02-18 | $5.25B 10-K · filed 2011-02-18 |
| 2008-09-30 | $2.58B 10-Q · filed 2009-10-22 | $3.34B derived: sum of 2 quarters · filed 2009-10-22 | $4.00B 10-Q · filed 2009-10-22 | |
| 2008-06-30 | $764.00M 10-Q · filed 2009-07-23 | $1.43B 10-Q · filed 2009-07-23 | ||
| 2007-12-31 | $2.17B 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |